Clover Health Investments, CORP /DE 8-K filings

Clover Health Investments Corp. has updated its bylaws, effective June 19, 2024, to revise the definition of 'Acting in Concert'.

Clover Health's PPO Medicare Advantage plans received a 0.5-star increase in their CMS rating, moving from 3.0 to 3.5 stars for the 2025 payment year.

Clover Health held its 2024 Annual Meeting of Stockholders, where shareholders voted on the election of directors, executive compensation, and the ratification of the company's auditor.

Clover Health is making its clinical decision support tool, Clover Assistant, available to external payors and providers under the new brand name Counterpart Assistant.

Clover Health reports a profitable first quarter on an Adjusted EBITDA basis, driven by revenue growth and improved medical care ratios, and announces a $20 million share repurchase program.

Clover Health has appointed Peter Kuipers as its new Chief Financial Officer, effective after the filing of the Q1 2024 report.

Clover Health Investments, Corp. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Clover Health has agreed to a settlement in multiple shareholder derivative lawsuits, requiring the company to implement a series of corporate governance enhancements.

Clover Health significantly improved its financial performance in 2023, reducing net losses and improving its Insurance Medical Care Ratio (MCR), and has issued guidance for 2024.